Key result
Analysis of 453 bovine samples identified 176 FMDv positive cases, with vaccine matching producing r1-values ≥0.3, indicating current vaccines remain fit-for-purpose against circulating strains.
Why the study?
Foot-and-mouth disease virus mutates rapidly, potentially reducing vaccine cross-protection against new lineages, necessitating evaluation of outbreak topotypes and vaccine efficacy in southern Africa.
Observational (n=453)
Yes
Current FMD vaccines remain effective against circulating SAT serotypes in southern Africa, with no new lineages identified between 2014 and 2018.
May support regional FMD vaccination; leaves open need for prospective antigenic surveillance.
Foot-and-mouth disease (FMD) virus (FMDv), like other ribonucleic acid (RNA) genome viruses, has a tendency to mutate rapidly. As such, available vaccines may not confer enough cross-protection against incursion of new lineages and sublineages. This paper is a retrospective study to determine the topotypes/lineages that caused previous FMD outbreaks in 6 southern African countries and the efficacy of the current vaccines to protect cattle against them. A total of 453 bovine epithelial tissue samples from 33 FMD outbreaks that occurred in these countries from 2014 to 2018 were investigated for the presence of FMDv. The genetic diversity of the identified Southern African Type (SAT)-FMD viruses was determined by comparing sequences from outbreaks and historical prototype sequences. Of the 453 samples investigated, 176 were positive for four FMDv serotypes. Out of the 176 FMD positive cases there were 105 SAT2 samples, 32 SAT1 samples, 21 SAT3 samples, and 18 serotype O samples. Phylogenetic analysis grouped the SATs VP1 gene sequences into previously observed topotypes in southern Africa. SAT1 viruses were from topotypes I and III, SAT2 viruses belonged to topotypes I, II, III, and IV, and SAT3 viruses were of topotypes I and II. Vaccine matching studies on the field FMDv isolates produced r1-values greater than or equal to 0.3 for the three SAT serotypes. This suggests that there is no significant antigenic difference between current SAT FMD vaccine strains and the circulating SAT serotypes. Therefore, the vaccines are still fit-purpose for the control FMD in the region. The study did not identify incursion of any new lineages/topotypes of FMD into the sampled southern African countries.
No takes yet. Share an insight, caveat, or question.
Fana et al. (2021) conducted an observational in Foot-and-mouth disease (n=453). Circulating FMDv lineages was evaluated on FMDv topotypes/lineages and vaccine matching (r1-values). Analysis of 453 bovine samples identified 176 FMDv positive cases, with vaccine matching producing r1-values ≥0.3, indicating current vaccines remain fit-for-purpose against circulating strains.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: